Avoro Capital Advisors Adds $23M in Celcuity Inc. ($CELC)
Key Points
- Avoro Capital Advisors changed its Celcuity Inc. ($CELC) stake by 8.5% last quarter, boosting to 3,375,000 shares worth $298.86 million.
- Wall Street's consensus rating on $CELC is Strong Buy and an average price target of $161.09.
- $CELC last traded around $88.55.
Avoro Capital Advisors increased its position in Celcuity Inc. ($CELC) by 8.5% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,375,000 shares of Celcuity Inc. after buying 263,889 shares during the quarter. Avoro Capital Advisors's holdings in Celcuity Inc. were worth $298.86 million as of its most recent filing.
Celcuity Inc. ($CELC) Stock
Celcuity Inc. Earnings
Analysts Set New Price Targets
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.